Ibrutinib Plus Rituximab Elicits High Responses in Indolent Mantle Cell Lymphoma
16457
post-template-default,single,single-post,postid-16457,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Ibrutinib Plus Rituximab Elicits High Responses in Indolent Mantle Cell Lymphoma

Home > Blogs  > Ibrutinib Plus Rituximab Elicits High Responses in Indolent Mantle Cell Lymphoma

16 Apr Ibrutinib Plus Rituximab Elicits High Responses in Indolent Mantle Cell Lymphoma

Posted at 11:30h in Blogs by

Indolent MCL patients treated with frontline ibrutinib plus rituximab showed an overall response of 84% after 12 cycles of treatment, with 80% of patients experiencing a CR. Undetectable MRD in the peripheral blood was achieved in 87% of patients. The estimated PFS at 36 months was 93%. At 2 years, 69% of patients could discontinue ibrutinib because of undetectable MRD. (Ref: Giné E et al. J Clin Oncol. 2022)
#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6921011455219646464

No Comments

Sorry, the comment form is closed at this time.